Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 3INTERVENTIONAL

Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis

Benefits of Inhalation of Hypertonic Saline Solution Prior to ELTGOL Physiotherapy in Bronchiectasis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Bronchiectasis is a chronic bronchial disease in which the usual capacity to remove secretions does not function correctly, causing mucus retention that leads to chronic infection. As with all infections, the use of antibiotics and puss removal are essential treatment elements. Physiotherapeutic techniques are used to assist in the removal of secretions, although these are time-consuming practices that need to be much better studied and which patients often do not continue practicing diligently. A physiotherapeutic technique called (Slow prolonged expiration in lateral decubitus) ELTGOL has been shown to be somewhat effective but as the mucus is viscous in this disorder, it can be difficult to get it to move. It is thought that saline solution inhalations may reduce mucus viscosity and could help to ease expectoration, facilitating the removal of the mucus by the physiotherapeutic technique. This project aims to test this hypothesis, which if true could represent an advance in the treatment of this severely debilitating disease.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult patients with bronchiectasis confirmed by high resolution computed tomography - No exacerbations in the previous month - Chronic mucopurulent and purulent sputum - ≥10ml daily expectoration - At least one exacerbation in the previous year - (Forced expiratory volume the 1st second) FEV1 ≥30% after bronchodilation - Sign the willing to sign a consent form Who Should NOT Join This Trial: - Current smokers or a smoking history of ≥20 p-y - Asthma, allergic bronchopulmonary aspergillosis or Cystic Fibrosis - Pregnant or lactating women - Following mucoactive treatment in the previous month - Inability to perform ELTGOL, spirometry or to attend visits - Practicing pulmonary rehabilitation in the previous 6 months - Change of treatment the previous month - Uncontrolled hypertension Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult patients with bronchiectasis confirmed by high resolution computed tomography * No exacerbations in the previous month * Chronic mucopurulent and purulent sputum * ≥10ml daily expectoration * At least one exacerbation in the previous year * (Forced expiratory volume the 1st second) FEV1 ≥30% after bronchodilation * Sign the informed consent Exclusion Criteria: * Current smokers or a smoking history of ≥20 p-y * Asthma, allergic bronchopulmonary aspergillosis or Cystic Fibrosis * Pregnant or lactating women * Following mucoactive treatment in the previous month * Inability to perform ELTGOL, spirometry or to attend visits * Practicing pulmonary rehabilitation in the previous 6 months * Change of treatment the previous month * Uncontrolled hypertension

Treatments Being Tested

OTHER

Hypertonic saline

Patients from intervention group will inhale hypertonic saline solution 5 minutes before performing the morning ELTGOL technique

DRUG

Isotonic saline

Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique

OTHER

ELTGOL

Patients from control group will perform the ELTGOL technique twice-daily

Locations (1)

University Hospital of Girona Dr. Josep Trueta
Girona, Spain